A Study of Avastin (Bevacizumab) and TACE Treatment in Patients With Liver Cancer.

• Overall response rate, time to progression, disease control rate, overall survival, tumor necrosis rate. [ Time Frame: Event driven ] [ Designated as safety issue: No ]
• AEs, laboratory parameters. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

This single arm, open label study will assess the efficacy and safety of Avastin treatment combined with transarterial chemoembolisation (TACE) in patients with localised unresectable liver cancer. Patients will be treated with TACE at 8 or 10 week intervals, and Avastin 5mg/kg iv will be administered 24-48 hours prior to first TACE and every 2 weeks thereafter. The anticipated time on study treatment is until disease progression or unmanageable toxicity, and the target sample size is <100 individuals.

Inclusion Criteria:

• adult patients, >=18 years of age;
• liver cancer, not suitable for resection;
• at least one measurable lesion, and overall tumor lesions occupying <50% of liver volume;
• ECOG performance status 0-2.

Exclusion Criteria:

• patients receiving concurrent radiotherapy or immunotherapy;
• patients who have received previous chemotherapy, biological agents or radiotherapy;
• prior TACE or TAE;
• prior liver transplantation or liver resection;
• current or recent (within 10 days of study start) use of full-dose anticoagulants for therapeutic purposes;
• patients with high risk esophageal/gastric varices.